

Shinsuke Uchikawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3132093/publications.pdf>

Version: 2024-02-01

46
papers

596
citations

623574

14
h-index

677027

22
g-index

47
all docs

47
docs citations

47
times ranked

828
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2019, 97, 75-81. | 0.9 | 44 |
| 2 | Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355. | 2.0 | 43 |
| 3 | Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820. | 1.8 | 41 |
| 4 | Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517. | 0.9 | 38 |
| 5 | Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00179. | 1.3 | 37 |
| 6 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222. | 0.9 | 33 |
| 7 | Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. <i>Cancers</i> , 2021, 13, 3958. | 1.7 | 29 |
| 8 | Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786. | 1.4 | 28 |
| 9 | Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155. | 4.2 | 27 |
| 10 | Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888. | 1.8 | 27 |
| 11 | Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797. | 0.9 | 26 |
| 12 | Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215. | 3.5 | 23 |
| 13 | Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160. | 4.2 | 20 |
| 14 | Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306. | 0.8 | 17 |
| 15 | Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226. | 2.3 | 16 |
| 16 | Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872. | 0.4 | 16 |
| 17 | Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828. | 1.2 | 14 |
| 18 | Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130. | 1.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101. | 1.6 | 13 |
| 20 | Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419. | 1.4 | 10 |
| 21 | Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2020, 98, 727-733. | 0.9 | 8 |
| 22 | Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2247. | 1.7 | 8 |
| 23 | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. <i>Medicine (United States)</i> , 2021, 100, e27576. | 0.4 | 8 |
| 24 | Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 320. | 1.7 | 8 |
| 25 | Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346. | 0.4 | 6 |
| 26 | Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1685-1693. | 1.4 | 5 |
| 27 | Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335. | 0.9 | 5 |
| 28 | Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 592-599. | 1.4 | 5 |
| 29 | Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. <i>Liver Cancer</i> , 2022, 11, 329-340. | 4.2 | 5 |
| 30 | Early experience of seven hepatocellular carcinoma cases treated with regorafenib. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2217-2223. | 0.2 | 4 |
| 31 | The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment. <i>PLoS ONE</i> , 2022, 17, e0262675. | 1.1 | 4 |
| 32 | A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843. | 0.4 | 3 |
| 33 | Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 0, , . | 4.2 | 3 |
| 34 | Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. <i>Internal Medicine</i> , 2021, 60, 829-837. | 0.3 | 2 |
| 35 | The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 443-450. | 0.6 | 2 |
| 36 | Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. <i>Internal Medicine</i> , 2021, 60, 2047-2053. | 0.3 | 1 |
| 38 | A case of primary hepatic leiomyosarcoma. <i>Acta Hepatologica Japonica</i> , 2019, 60, 358-365. | 0.0 | 1 |
| 39 | Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the <i>ATP8B1</i> Gene. <i>Case Reports in Gastroenterology</i> , 2022, 16, 110-115. | 0.3 | 1 |
| 40 | Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study. <i>BMC Gastroenterology</i> , 2022, 22, . | 0.8 | 1 |
| 41 | Reply from the authors. <i>Hepatology Research</i> , 2020, 50, 1393-1393. | 1.8 | 0 |
| 42 | A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system. <i>IDCases</i> , 2021, 23, e01059. | 0.4 | 0 |
| 43 | A case of successful repeated lusutrombopag administration for thrombocytopenia in a patient with cirrhosis requiring multiple invasive procedures. <i>Acta Hepatologica Japonica</i> , 2021, 62, 136-143. | 0.0 | 0 |
| 44 | A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309. | 0.0 | 0 |
| 45 | Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1517-1524. | 0.4 | 0 |
| 46 | A patient with polycystic liver disease combined with portal hypertension that died due to bacterial peritonitis as a secondary cause of death. <i>Acta Hepatologica Japonica</i> , 2022, 63, 279-285. | 0.0 | 0 |